BIOCOM CEO Breakfast Series, Part 2

Jul. 28, 2010
La Jolla Marriott
San Diego, CA
www.biocom.org

Description:

Reimbursement: The New Investment Hurdle

Campbell Alliance is collaborating with BIOCOM to offer a four-part CEO Breakfast Series to address critical issues facing the current generation of C-suite executives in the pharmaceutical and biotech industries. The second event in this series will focus on considering reimbursement issues early in the commercialization process.

This event is offered complimentary to CEOs at pharmaceutical and biotech companies.

Abstract:

Reimbursement: The New Investment Hurdle

Speakers:

Jon McGarity, Executive Vice President, Campbell Alliance

Lujing Wang, Senior Vice President and Practice Area Leader, Campbell Alliance

Michael Fleming, Vice President, Campbell Alliance

Reimbursement: The New Investment Hurdle

With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element senior executives must evaluate. Payors' increased power to restrict access and contract for reduced prices-combined with the growing use of evidence-based medicine to influence reimbursement policy-can profoundly impact potential revenues and by extension, asset valuations. Many executives responsible for licensing decisions have ignored this increasingly important and critical driver of valuation. At best, they begrudgingly recognize that they need to consider scenarios of price and access within their forecast models. Instead, they should embrace a nuanced knowledge of the payor environment as a means of differentiation.

Licensing executives are well aware of the fast-changing reimbursement climate, but too often their inability to gauge payors' potential actions results in a "just say no" approach to certain deals. Instead, licensing parties should develop new deal structures including reimbursement-based milestones to limit potential risk associated with a diverse payor community. With a nuanced approach to payors and a strategic perspective on reimbursement, licensing teams-and those executives managing them-can find value others may have missed and avoid missteps driven by conventional thinking.

View Entire Event Calendar

Don't Miss